Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C
AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection
Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients
Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection
Sofosbuvir/ledipasvir and AbbVie 2D regimen cure most people with HCV genotype 4
Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis
Sustained virological response to hepatitis C treatment reduces mortality, liver cancer and liver transplants
Sofosbuvir/ledipasvir cures nearly all genotype 1 HCV for people with HIV co-infection
